top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.

Biblioteca

MARC Lista (tabellare)
Pediatric psychopharmacology : principles and practice / / edited by Andr�es Martin [and others] [[electronic resource]]
Pediatric psychopharmacology : principles and practice / / edited by Andr�es Martin [and others] [[electronic resource]]
Edizione [1st ed.]
Pubbl/distr/stampa Oxford ; ; New York : , : Oxford University Press, , 2023
Descrizione fisica 1 online resource (814 p.)
Disciplina 615/.78
Collana Oxford scholarship online
Soggetto topico Pediatric psychopharmacology
Psychotropic drugs
ISBN 0-19-770826-9
1-280-83504-4
9786610835041
0-19-803245-5
1-4237-4569-8
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Contents; Contributors; SECTION I: BIOLOGICAL BASES OF PEDIATRIC PSYCHOPHARMACOLOGY; I-A: DEVELOPMENTAL PRINCIPLES OF NEUROBIOLOGY AND PSYCHOPHARMACOLOGY; 1. Overview of Brain Development; 2. Synaptic Function and Biochemical Neuroanatomy; 3. Mechanisms of Signal Transduction and Adaptation to Psychotropic Drug Action; 4. Pharmacokinetics I: Developmental Principles; 5. Pharmacokinetics II: Cytochrome P450-Mediated Drug Interactions; I-B: GENETIC PRINCIPLES; 6. Molecular Genetics; 7. Pharmacogenetics; I-C: DEVELOPMENTAL PSYCHOPATHOLOGY
8. Neurobiology of Attention Regulation and its Disorders9. Neurobiology of Early-Life Stress and its Disorders; 10. Neurobiology of Early-Onset Mood Disorders; 11. Neurobiology of Early-Onset Anxiety Disorders; 12. Neurobiology of Obsessive-Compulsive Disorder; 13. Neurobiology of Tic Disorders, Including Tourette's Syndrome; 14. Neurobiology of Immune-Mediated Neuropsychiatric Disorders; 15. Neurobiology of Childhood Schizophrenia and Related Disorders; 16. Neurobiology of Affiliation: Implications for Autism Spectrum Disorders; 17. Neurobiology of Aggression
18. Neurobiology of Eating Disorders19. Neurobiology of Substance Abuse and Dependence Disorders; SECTION II: SOMATIC INTERVENTIONS; II-A: PSYCHOTROPIC AGENTS; 20. Stimulants; 21. Adrenergic Agonists: Clonidine and Guanfacine; 22. Antidepressants I: Selective Serotonin Reuptake Inhibitors; 23. Antidepressants II: Tricyclic Agents; 24. Antidepressants III: Other Agents; 25. Mood Stabilizers: Lithium and Anticonvulsants; 26. Antipsychotic Agents: Traditional and Atypical; 27. Anxiolytics: Benzodiazepines, Buspirone, and Others; 28. Miscellaneous Compounds: Beta-Blockers and Opiate Antagonists
II-B: OTHER SOMATIC INTERVENTIONS29. Complementary and Alternative Medicine in Pediatric Psychopharmacology; 30. Electroconvulsive Therapy and Transcranial Magnetic Stimulation; SECTION III: ASSESSMENT AND TREATMENT; III-A: GENERAL PRINCIPLES; 31. Clinical Assessment of Children and Adolescents Treated Pharmacologically; 32. Clinical Instruments and Scales in Pediatric Psychopharmacology; 33. Thinking About Prescribing: The Psychology of Psychopharmacology; 34. Combining Pharmacotherapy and Psychotherapy: An Evidence-Based Approach; III-B: SPECIFIC DISORDERS AND SYNDROMES
35. Attention-Deficit Hyperactivity Disorder36. Depressive Disorders; 37. Bipolar Disorder; 38. Anxiety Disorders; 39. Obsessive-Compulsive Disorder; 40. Tourette's Syndrome and Other Tic Disorders; 41. Early-Onset Schizophrenia; 42. Autistic and Other Pervasive Developmental Disorders; 43. Post-traumatic Stress Disorder; 44. Eating Disorders; III-C: SPECIAL CLINICAL POPULATIONS; 45. Substance-Abusing Youths; 46. Individuals with Mental Retardation; 47. The Medically Ill Child or Adolescent; 48. Psychopharmacology During Pregnancy: Infant Considerations
49. Psychopharmacological Treatment of Preschoolers
Record Nr. UNINA-9910808144703321
Oxford ; ; New York : , : Oxford University Press, , 2023
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Pediatric psychopharmacology [[electronic resource] ] : principles and practice / / edited by Andrés Martin ... [et al.]
Pediatric psychopharmacology [[electronic resource] ] : principles and practice / / edited by Andrés Martin ... [et al.]
Pubbl/distr/stampa Oxford ; ; New York, : Oxford University Press, c2003
Descrizione fisica 1 online resource (814 p.)
Disciplina 615/.78
Altri autori (Persone) MartinAndrés
Soggetto topico Pediatric psychopharmacology
Psychotropic drugs
Soggetto genere / forma Electronic books.
ISBN 1-280-83504-4
9786610835041
0-19-803245-5
1-4237-4569-8
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Contents; Contributors; SECTION I: BIOLOGICAL BASES OF PEDIATRIC PSYCHOPHARMACOLOGY; I-A: DEVELOPMENTAL PRINCIPLES OF NEUROBIOLOGY AND PSYCHOPHARMACOLOGY; 1. Overview of Brain Development; 2. Synaptic Function and Biochemical Neuroanatomy; 3. Mechanisms of Signal Transduction and Adaptation to Psychotropic Drug Action; 4. Pharmacokinetics I: Developmental Principles; 5. Pharmacokinetics II: Cytochrome P450-Mediated Drug Interactions; I-B: GENETIC PRINCIPLES; 6. Molecular Genetics; 7. Pharmacogenetics; I-C: DEVELOPMENTAL PSYCHOPATHOLOGY
8. Neurobiology of Attention Regulation and its Disorders9. Neurobiology of Early-Life Stress and its Disorders; 10. Neurobiology of Early-Onset Mood Disorders; 11. Neurobiology of Early-Onset Anxiety Disorders; 12. Neurobiology of Obsessive-Compulsive Disorder; 13. Neurobiology of Tic Disorders, Including Tourette's Syndrome; 14. Neurobiology of Immune-Mediated Neuropsychiatric Disorders; 15. Neurobiology of Childhood Schizophrenia and Related Disorders; 16. Neurobiology of Affiliation: Implications for Autism Spectrum Disorders; 17. Neurobiology of Aggression
18. Neurobiology of Eating Disorders19. Neurobiology of Substance Abuse and Dependence Disorders; SECTION II: SOMATIC INTERVENTIONS; II-A: PSYCHOTROPIC AGENTS; 20. Stimulants; 21. Adrenergic Agonists: Clonidine and Guanfacine; 22. Antidepressants I: Selective Serotonin Reuptake Inhibitors; 23. Antidepressants II: Tricyclic Agents; 24. Antidepressants III: Other Agents; 25. Mood Stabilizers: Lithium and Anticonvulsants; 26. Antipsychotic Agents: Traditional and Atypical; 27. Anxiolytics: Benzodiazepines, Buspirone, and Others; 28. Miscellaneous Compounds: Beta-Blockers and Opiate Antagonists
II-B: OTHER SOMATIC INTERVENTIONS29. Complementary and Alternative Medicine in Pediatric Psychopharmacology; 30. Electroconvulsive Therapy and Transcranial Magnetic Stimulation; SECTION III: ASSESSMENT AND TREATMENT; III-A: GENERAL PRINCIPLES; 31. Clinical Assessment of Children and Adolescents Treated Pharmacologically; 32. Clinical Instruments and Scales in Pediatric Psychopharmacology; 33. Thinking About Prescribing: The Psychology of Psychopharmacology; 34. Combining Pharmacotherapy and Psychotherapy: An Evidence-Based Approach; III-B: SPECIFIC DISORDERS AND SYNDROMES
35. Attention-Deficit Hyperactivity Disorder36. Depressive Disorders; 37. Bipolar Disorder; 38. Anxiety Disorders; 39. Obsessive-Compulsive Disorder; 40. Tourette's Syndrome and Other Tic Disorders; 41. Early-Onset Schizophrenia; 42. Autistic and Other Pervasive Developmental Disorders; 43. Post-traumatic Stress Disorder; 44. Eating Disorders; III-C: SPECIAL CLINICAL POPULATIONS; 45. Substance-Abusing Youths; 46. Individuals with Mental Retardation; 47. The Medically Ill Child or Adolescent; 48. Psychopharmacology During Pregnancy: Infant Considerations
49. Psychopharmacological Treatment of Preschoolers
Record Nr. UNINA-9910451833303321
Oxford ; ; New York, : Oxford University Press, c2003
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Pediatric psychopharmacology [[electronic resource] ] : principles and practice / / edited by Andrés Martin ... [et al.]
Pediatric psychopharmacology [[electronic resource] ] : principles and practice / / edited by Andrés Martin ... [et al.]
Pubbl/distr/stampa Oxford ; ; New York, : Oxford University Press, c2003
Descrizione fisica 1 online resource (814 p.)
Disciplina 615/.78
Altri autori (Persone) MartinAndrés
Soggetto topico Pediatric psychopharmacology
Psychotropic drugs
ISBN 0-19-770826-9
1-280-83504-4
9786610835041
0-19-803245-5
1-4237-4569-8
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Contents; Contributors; SECTION I: BIOLOGICAL BASES OF PEDIATRIC PSYCHOPHARMACOLOGY; I-A: DEVELOPMENTAL PRINCIPLES OF NEUROBIOLOGY AND PSYCHOPHARMACOLOGY; 1. Overview of Brain Development; 2. Synaptic Function and Biochemical Neuroanatomy; 3. Mechanisms of Signal Transduction and Adaptation to Psychotropic Drug Action; 4. Pharmacokinetics I: Developmental Principles; 5. Pharmacokinetics II: Cytochrome P450-Mediated Drug Interactions; I-B: GENETIC PRINCIPLES; 6. Molecular Genetics; 7. Pharmacogenetics; I-C: DEVELOPMENTAL PSYCHOPATHOLOGY
8. Neurobiology of Attention Regulation and its Disorders9. Neurobiology of Early-Life Stress and its Disorders; 10. Neurobiology of Early-Onset Mood Disorders; 11. Neurobiology of Early-Onset Anxiety Disorders; 12. Neurobiology of Obsessive-Compulsive Disorder; 13. Neurobiology of Tic Disorders, Including Tourette's Syndrome; 14. Neurobiology of Immune-Mediated Neuropsychiatric Disorders; 15. Neurobiology of Childhood Schizophrenia and Related Disorders; 16. Neurobiology of Affiliation: Implications for Autism Spectrum Disorders; 17. Neurobiology of Aggression
18. Neurobiology of Eating Disorders19. Neurobiology of Substance Abuse and Dependence Disorders; SECTION II: SOMATIC INTERVENTIONS; II-A: PSYCHOTROPIC AGENTS; 20. Stimulants; 21. Adrenergic Agonists: Clonidine and Guanfacine; 22. Antidepressants I: Selective Serotonin Reuptake Inhibitors; 23. Antidepressants II: Tricyclic Agents; 24. Antidepressants III: Other Agents; 25. Mood Stabilizers: Lithium and Anticonvulsants; 26. Antipsychotic Agents: Traditional and Atypical; 27. Anxiolytics: Benzodiazepines, Buspirone, and Others; 28. Miscellaneous Compounds: Beta-Blockers and Opiate Antagonists
II-B: OTHER SOMATIC INTERVENTIONS29. Complementary and Alternative Medicine in Pediatric Psychopharmacology; 30. Electroconvulsive Therapy and Transcranial Magnetic Stimulation; SECTION III: ASSESSMENT AND TREATMENT; III-A: GENERAL PRINCIPLES; 31. Clinical Assessment of Children and Adolescents Treated Pharmacologically; 32. Clinical Instruments and Scales in Pediatric Psychopharmacology; 33. Thinking About Prescribing: The Psychology of Psychopharmacology; 34. Combining Pharmacotherapy and Psychotherapy: An Evidence-Based Approach; III-B: SPECIFIC DISORDERS AND SYNDROMES
35. Attention-Deficit Hyperactivity Disorder36. Depressive Disorders; 37. Bipolar Disorder; 38. Anxiety Disorders; 39. Obsessive-Compulsive Disorder; 40. Tourette's Syndrome and Other Tic Disorders; 41. Early-Onset Schizophrenia; 42. Autistic and Other Pervasive Developmental Disorders; 43. Post-traumatic Stress Disorder; 44. Eating Disorders; III-C: SPECIAL CLINICAL POPULATIONS; 45. Substance-Abusing Youths; 46. Individuals with Mental Retardation; 47. The Medically Ill Child or Adolescent; 48. Psychopharmacology During Pregnancy: Infant Considerations
49. Psychopharmacological Treatment of Preschoolers
Record Nr. UNINA-9910777539803321
Oxford ; ; New York, : Oxford University Press, c2003
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Prescribing mental health medication : the practitioner's guide / / Christopher M. Doran
Prescribing mental health medication : the practitioner's guide / / Christopher M. Doran
Autore Doran Christopher M. <1946-, >
Edizione [2nd ed.]
Pubbl/distr/stampa Abingdon, Oxon : , : Routledge, , 2013
Descrizione fisica 1 online resource (579 p.)
Disciplina 615/.78
Soggetto topico Psychotropic drugs
Psychopharmacology
Drugs - Prescribing
Soggetto genere / forma Electronic books.
ISBN 0-203-11182-6
1-299-38679-2
1-136-28010-3
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto pt. 1. The need for this book -- pt. 2. Medication management start to finish -- pt. 3. Medicating speical populations -- pt. 4. Medication dilemmas and their clinical management -- pt. 5. Competent clinical practice.
Record Nr. UNINA-9910452460703321
Doran Christopher M. <1946-, >  
Abingdon, Oxon : , : Routledge, , 2013
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Principles of CNS drug development [[electronic resource] ] : from test tube to patient / / John Kelly
Principles of CNS drug development [[electronic resource] ] : from test tube to patient / / John Kelly
Autore Kelly John <1961->
Pubbl/distr/stampa Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009
Descrizione fisica 1 online resource (326 p.)
Disciplina 615/.78
Soggetto topico Neuropharmacology
Drug development
ISBN 1-282-36283-6
9786612362835
0-470-68292-2
0-470-68291-4
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Principles of CNS drug development; Contents; Acknowledgements; Preface; Abbreviations; 1 Introduction; 1.1 The global burden of CNS disease; 1.2 Assessment of the global burden of disease; 1.3 The prevalence of CNS disorders; 1.4 Disability due to CNS disorders; 1.5 Economic Costs; 1.6 Concluding comments; References; 2 An overview of the major CNS disorders; 2.1 Introduction; 2.2 Overview of psychiatric disorders; 2.3 Overview of neurological/neurodegenerative disorders; 2.4 Concluding comments; References; 3 Neurobiological substrates of CNS disorders; 3.1 Introduction
3.2 Brief introduction to the principles of chemical neurotransmission3.3 Stages of chemical neurotransmission; 3.4 Approaches to investigating CNS alterations in CNS disorders; 3.5 Evidence for a neurobiological rationale for CNS disorders; 3.6 Concluding comments; References; 4 Current pharmacological targets; 4.1 Introduction; 4.2 Pharmacological treatments for depression; 4.3 Pharmacological treatments for schizophrenia; 4.4 Pharmacological treatments for anxiety disorders; 4.5 Pharmacological treatments for epilepsy; 4.6 Pharmacological treatments for Parkinson's disease
4.7 Pharmacological treatments for Alzheimer's disease4.8 Concluding comments; References; 5 Premarketing efficacy evaluation; 5.1 Introduction; 5.2 Target identification; 5.3 Lead optimisation; 5.4 Target validation in animal models; 5.5 The use of genetically modified animals in CNS drug development; 5.6 A selection of animal models of psychiatric disease; 5.7 A selection of animal models of neurodegenerative disease; 5.8 Which models to choose; 5.9 Clinical trials that evaluate drug efficacy; 5.10 Specific drug profiles; References
6 Pharmacokinetic considerations: Absorption, distribution, metabolism and elimination6.1 Introduction; 6.2 What are the 'ideal' pharmacokinetic properties for a CNS drug?; 6.3 Absorption; 6.4 Distribution; 6.5 Metabolism; 6.6 Elimination; 6.7 Measurement of drug concentrations; 6.8 Factors that affect pharmacokinetics; 6.9 Allometric scaling; 6.10 Microdosing (Phase 0) Studies; 6.11 Dose prediction and therapeutic drug monitoring; 6.12 Stereoselectivity of metabolism of drugs; 6.13 Specific drug profiles; 6.14 Concluding comments; References; 7 Safety concerns; 7.1 Introduction
7.2 Postmarketing surveillance7.3 Acute poisoning; 7.4 Quantification of the relative risk of fatalities from CNS drugs; 7.5 Adverse drug reactions (ADRs); 7.6 Specific types of toxicity encountered with psychotropic drugs; 7.7 Safety concerns following long-term administration of CNS Drugs; 7.8 Polypharmacy; 7.9 Specific drug profiles; 7.10 Concluding comments; References; Websites; 8 Preclinical and clinical safety evaluation; 8.1 Introduction; 8.2 Preclinical exploratory toxicology and safety pharmacology evaluations; 8.3 Primary and secondary pharmacology; 8.4 Safety pharmacology
8.5 Toxicology studies required for regulatory purposes
Record Nr. UNINA-9910139897403321
Kelly John <1961->  
Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Principles of CNS drug development [[electronic resource] ] : from test tube to patient / / John Kelly
Principles of CNS drug development [[electronic resource] ] : from test tube to patient / / John Kelly
Autore Kelly John <1961->
Pubbl/distr/stampa Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009
Descrizione fisica 1 online resource (326 p.)
Disciplina 615/.78
Soggetto topico Neuropharmacology
Drug development
ISBN 1-282-36283-6
9786612362835
0-470-68292-2
0-470-68291-4
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Principles of CNS drug development; Contents; Acknowledgements; Preface; Abbreviations; 1 Introduction; 1.1 The global burden of CNS disease; 1.2 Assessment of the global burden of disease; 1.3 The prevalence of CNS disorders; 1.4 Disability due to CNS disorders; 1.5 Economic Costs; 1.6 Concluding comments; References; 2 An overview of the major CNS disorders; 2.1 Introduction; 2.2 Overview of psychiatric disorders; 2.3 Overview of neurological/neurodegenerative disorders; 2.4 Concluding comments; References; 3 Neurobiological substrates of CNS disorders; 3.1 Introduction
3.2 Brief introduction to the principles of chemical neurotransmission3.3 Stages of chemical neurotransmission; 3.4 Approaches to investigating CNS alterations in CNS disorders; 3.5 Evidence for a neurobiological rationale for CNS disorders; 3.6 Concluding comments; References; 4 Current pharmacological targets; 4.1 Introduction; 4.2 Pharmacological treatments for depression; 4.3 Pharmacological treatments for schizophrenia; 4.4 Pharmacological treatments for anxiety disorders; 4.5 Pharmacological treatments for epilepsy; 4.6 Pharmacological treatments for Parkinson's disease
4.7 Pharmacological treatments for Alzheimer's disease4.8 Concluding comments; References; 5 Premarketing efficacy evaluation; 5.1 Introduction; 5.2 Target identification; 5.3 Lead optimisation; 5.4 Target validation in animal models; 5.5 The use of genetically modified animals in CNS drug development; 5.6 A selection of animal models of psychiatric disease; 5.7 A selection of animal models of neurodegenerative disease; 5.8 Which models to choose; 5.9 Clinical trials that evaluate drug efficacy; 5.10 Specific drug profiles; References
6 Pharmacokinetic considerations: Absorption, distribution, metabolism and elimination6.1 Introduction; 6.2 What are the 'ideal' pharmacokinetic properties for a CNS drug?; 6.3 Absorption; 6.4 Distribution; 6.5 Metabolism; 6.6 Elimination; 6.7 Measurement of drug concentrations; 6.8 Factors that affect pharmacokinetics; 6.9 Allometric scaling; 6.10 Microdosing (Phase 0) Studies; 6.11 Dose prediction and therapeutic drug monitoring; 6.12 Stereoselectivity of metabolism of drugs; 6.13 Specific drug profiles; 6.14 Concluding comments; References; 7 Safety concerns; 7.1 Introduction
7.2 Postmarketing surveillance7.3 Acute poisoning; 7.4 Quantification of the relative risk of fatalities from CNS drugs; 7.5 Adverse drug reactions (ADRs); 7.6 Specific types of toxicity encountered with psychotropic drugs; 7.7 Safety concerns following long-term administration of CNS Drugs; 7.8 Polypharmacy; 7.9 Specific drug profiles; 7.10 Concluding comments; References; Websites; 8 Preclinical and clinical safety evaluation; 8.1 Introduction; 8.2 Preclinical exploratory toxicology and safety pharmacology evaluations; 8.3 Primary and secondary pharmacology; 8.4 Safety pharmacology
8.5 Toxicology studies required for regulatory purposes
Record Nr. UNINA-9910817296903321
Kelly John <1961->  
Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Principles of psychopharmacology for mental health professionals [[electronic resource] /] / Jeffrey E. Kelsey, D. Jeffrey Newport, Charles B. Nemeroff
Principles of psychopharmacology for mental health professionals [[electronic resource] /] / Jeffrey E. Kelsey, D. Jeffrey Newport, Charles B. Nemeroff
Autore Kelsey Jeffrey E
Pubbl/distr/stampa Hoboken, N.J., : Wiley-Liss, c2006
Descrizione fisica 1 online resource (411 p.)
Disciplina 615.78
615/.78
Altri autori (Persone) NewportD. Jeffrey
NemeroffCharles B
Soggetto topico Mental illness - Chemotherapy
Psychopharmacology
Soggetto genere / forma Electronic books.
ISBN 1-280-51752-2
9786610517527
0-470-30737-4
0-471-79463-5
0-471-79462-7
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto PRINCIPLES OF PSYCHOPHARMACOLOGY FOR MENTAL HEALTH PROFESSIONALS; CONTENTS; Preface; Faculty Disclosure; 1 INTRODUCTION AND OVERVIEW; Additional Reading; 2 BASICS OF PSYCHOPHARMACOLOGY; 2.1 Introduction; 2.1.1 Learning the Language of Pharmacology; 2.1.2 Overview; 2.2 Normal Human Nervous System; 2.2.1 Neuroanatomy: Structure of the Nervous System; 2.2.2 Neurophysiology: Function of the Nervous System; 2.3 Pathophysiology: Study of What Goes Wrong; 2.3.1 What Goes Wrong; 2.3.2 Why It Goes Wrong; 2.4 Pharmacology; 2.4.1 Introduction; 2.4.2 Pharmacokinetics; 2.4.3 Pharmacodynamics
2.4.4 Predicting Medication Effects2.4.5 Predicting Drug Interactions; 2.5 Putting It All Together; Additional Reading; 3 MOOD DISORDERS; 3.1 Introduction; 3.2 Major Depressive Disorder; 3.2.1 Brief Description and Diagnostic Criteria; 3.2.2 Prevalence and Risk Factors; 3.2.3 Presentation and Clinical Course; 3.2.4 Initial Evaluation and Differential Diagnosis; 3.2.5 History of Pharmacological Treatment; 3.2.6 Current Approach to Treatment; 3.2.7 Refractory Depression; 3.3 Dysthymic Disorder; 3.3.1 Brief Description and Diagnostic Criteria; 3.3.2 Prevalence and Risk Factors
3.3.3 Presentation and Clinical Course3.3.4 Initial Evaluation and Differential Diagnosis; 3.3.5 History of Pharmacological Treatment; 3.3.6 Current Approach to Treatment; 3.3.7 Refractory Depression; 3.4 Bipolar Disorders; 3.4.1 Brief Description and Diagnostic Criteria; 3.4.2 Prevalence and Risk Factors; 3.4.3 Presentation and Clinical Course; 3.4.4 Initial Evaluation and Differential Diagnosis; 3.4.5 History of Pharmacological Treatment; 3.4.6 Current Approach to Treatment; Additional Reading; 4 SCHIZOPHRENIA; 4.1 Brief Description and Diagnostic Criteria; 4.2 Prevalence and Risk Factors
4.3 Presentation and Clinical Course4.4 Initial Evaluation and Differential Diagnosis; 4.5 History of Treatment; 4.6 Current Approach to Treatment; 4.6.1 Prodromal Phase; 4.6.2 Acute Phase; 4.6.3 Maintenance Phase; 4.6.4 Residual Phase; 4.7 Treatment Resistant Schizophrenia; Additional Reading; 5 ANXIETY DISORDERS; 5.1 Introduction; 5.1.1 History of Anxiety Disorders; 5.1.2 Anxiety Symptoms; 5.1.3 Brief Overview of the Anxiety Disorders; 5.1.4 History of Pharmacological Treatment for Anxiety; 5.2 Panic Disorder; 5.2.1 Brief Description and Diagnostic Criteria
5.2.2 Prevalence and Risk Factors5.2.3 Presentation and Clinical Course; 5.2.4 Initial Evaluation and Differential Diagnosis; 5.2.5 History of Pharmacological Treatment; 5.2.6 Current Approach to Treatment; 5.3 Generalized Anxiety Disorder; 5.3.1 Brief Description and Diagnostic Criteria; 5.3.2 Prevalence and Risk Factors; 5.3.3 Presentation and Clinical Course; 5.3.4 Initial Evaluation and Differential Diagnosis; 5.3.5 History of Pharmacological Treatment; 5.3.6 Current Approach of Treatment; 5.4 Obsessive-Compulsive Disorder; 5.4.1 Brief Description and Diagnostic Criteria
5.4.2 Prevalence and Risk Factors
Record Nr. UNINA-9910143568403321
Kelsey Jeffrey E  
Hoboken, N.J., : Wiley-Liss, c2006
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Principles of psychopharmacology for mental health professionals [[electronic resource] /] / Jeffrey E. Kelsey, D. Jeffrey Newport, Charles B. Nemeroff
Principles of psychopharmacology for mental health professionals [[electronic resource] /] / Jeffrey E. Kelsey, D. Jeffrey Newport, Charles B. Nemeroff
Autore Kelsey Jeffrey E
Pubbl/distr/stampa Hoboken, N.J., : Wiley-Liss, c2006
Descrizione fisica 1 online resource (411 p.)
Disciplina 615.78
615/.78
Altri autori (Persone) NewportD. Jeffrey
NemeroffCharles B
Soggetto topico Mental illness - Chemotherapy
Psychopharmacology
ISBN 1-280-51752-2
9786610517527
0-470-30737-4
0-471-79463-5
0-471-79462-7
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto PRINCIPLES OF PSYCHOPHARMACOLOGY FOR MENTAL HEALTH PROFESSIONALS; CONTENTS; Preface; Faculty Disclosure; 1 INTRODUCTION AND OVERVIEW; Additional Reading; 2 BASICS OF PSYCHOPHARMACOLOGY; 2.1 Introduction; 2.1.1 Learning the Language of Pharmacology; 2.1.2 Overview; 2.2 Normal Human Nervous System; 2.2.1 Neuroanatomy: Structure of the Nervous System; 2.2.2 Neurophysiology: Function of the Nervous System; 2.3 Pathophysiology: Study of What Goes Wrong; 2.3.1 What Goes Wrong; 2.3.2 Why It Goes Wrong; 2.4 Pharmacology; 2.4.1 Introduction; 2.4.2 Pharmacokinetics; 2.4.3 Pharmacodynamics
2.4.4 Predicting Medication Effects2.4.5 Predicting Drug Interactions; 2.5 Putting It All Together; Additional Reading; 3 MOOD DISORDERS; 3.1 Introduction; 3.2 Major Depressive Disorder; 3.2.1 Brief Description and Diagnostic Criteria; 3.2.2 Prevalence and Risk Factors; 3.2.3 Presentation and Clinical Course; 3.2.4 Initial Evaluation and Differential Diagnosis; 3.2.5 History of Pharmacological Treatment; 3.2.6 Current Approach to Treatment; 3.2.7 Refractory Depression; 3.3 Dysthymic Disorder; 3.3.1 Brief Description and Diagnostic Criteria; 3.3.2 Prevalence and Risk Factors
3.3.3 Presentation and Clinical Course3.3.4 Initial Evaluation and Differential Diagnosis; 3.3.5 History of Pharmacological Treatment; 3.3.6 Current Approach to Treatment; 3.3.7 Refractory Depression; 3.4 Bipolar Disorders; 3.4.1 Brief Description and Diagnostic Criteria; 3.4.2 Prevalence and Risk Factors; 3.4.3 Presentation and Clinical Course; 3.4.4 Initial Evaluation and Differential Diagnosis; 3.4.5 History of Pharmacological Treatment; 3.4.6 Current Approach to Treatment; Additional Reading; 4 SCHIZOPHRENIA; 4.1 Brief Description and Diagnostic Criteria; 4.2 Prevalence and Risk Factors
4.3 Presentation and Clinical Course4.4 Initial Evaluation and Differential Diagnosis; 4.5 History of Treatment; 4.6 Current Approach to Treatment; 4.6.1 Prodromal Phase; 4.6.2 Acute Phase; 4.6.3 Maintenance Phase; 4.6.4 Residual Phase; 4.7 Treatment Resistant Schizophrenia; Additional Reading; 5 ANXIETY DISORDERS; 5.1 Introduction; 5.1.1 History of Anxiety Disorders; 5.1.2 Anxiety Symptoms; 5.1.3 Brief Overview of the Anxiety Disorders; 5.1.4 History of Pharmacological Treatment for Anxiety; 5.2 Panic Disorder; 5.2.1 Brief Description and Diagnostic Criteria
5.2.2 Prevalence and Risk Factors5.2.3 Presentation and Clinical Course; 5.2.4 Initial Evaluation and Differential Diagnosis; 5.2.5 History of Pharmacological Treatment; 5.2.6 Current Approach to Treatment; 5.3 Generalized Anxiety Disorder; 5.3.1 Brief Description and Diagnostic Criteria; 5.3.2 Prevalence and Risk Factors; 5.3.3 Presentation and Clinical Course; 5.3.4 Initial Evaluation and Differential Diagnosis; 5.3.5 History of Pharmacological Treatment; 5.3.6 Current Approach of Treatment; 5.4 Obsessive-Compulsive Disorder; 5.4.1 Brief Description and Diagnostic Criteria
5.4.2 Prevalence and Risk Factors
Record Nr. UNINA-9910830140903321
Kelsey Jeffrey E  
Hoboken, N.J., : Wiley-Liss, c2006
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Principles of psychopharmacology for mental health professionals [[electronic resource] /] / Jeffrey E. Kelsey, D. Jeffrey Newport, Charles B. Nemeroff
Principles of psychopharmacology for mental health professionals [[electronic resource] /] / Jeffrey E. Kelsey, D. Jeffrey Newport, Charles B. Nemeroff
Autore Kelsey Jeffrey E
Pubbl/distr/stampa Hoboken, N.J., : Wiley-Liss, c2006
Descrizione fisica 1 online resource (411 p.)
Disciplina 615.78
615/.78
Altri autori (Persone) NewportD. Jeffrey
NemeroffCharles B
Soggetto topico Mental illness - Chemotherapy
Psychopharmacology
ISBN 1-280-51752-2
9786610517527
0-470-30737-4
0-471-79463-5
0-471-79462-7
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto PRINCIPLES OF PSYCHOPHARMACOLOGY FOR MENTAL HEALTH PROFESSIONALS; CONTENTS; Preface; Faculty Disclosure; 1 INTRODUCTION AND OVERVIEW; Additional Reading; 2 BASICS OF PSYCHOPHARMACOLOGY; 2.1 Introduction; 2.1.1 Learning the Language of Pharmacology; 2.1.2 Overview; 2.2 Normal Human Nervous System; 2.2.1 Neuroanatomy: Structure of the Nervous System; 2.2.2 Neurophysiology: Function of the Nervous System; 2.3 Pathophysiology: Study of What Goes Wrong; 2.3.1 What Goes Wrong; 2.3.2 Why It Goes Wrong; 2.4 Pharmacology; 2.4.1 Introduction; 2.4.2 Pharmacokinetics; 2.4.3 Pharmacodynamics
2.4.4 Predicting Medication Effects2.4.5 Predicting Drug Interactions; 2.5 Putting It All Together; Additional Reading; 3 MOOD DISORDERS; 3.1 Introduction; 3.2 Major Depressive Disorder; 3.2.1 Brief Description and Diagnostic Criteria; 3.2.2 Prevalence and Risk Factors; 3.2.3 Presentation and Clinical Course; 3.2.4 Initial Evaluation and Differential Diagnosis; 3.2.5 History of Pharmacological Treatment; 3.2.6 Current Approach to Treatment; 3.2.7 Refractory Depression; 3.3 Dysthymic Disorder; 3.3.1 Brief Description and Diagnostic Criteria; 3.3.2 Prevalence and Risk Factors
3.3.3 Presentation and Clinical Course3.3.4 Initial Evaluation and Differential Diagnosis; 3.3.5 History of Pharmacological Treatment; 3.3.6 Current Approach to Treatment; 3.3.7 Refractory Depression; 3.4 Bipolar Disorders; 3.4.1 Brief Description and Diagnostic Criteria; 3.4.2 Prevalence and Risk Factors; 3.4.3 Presentation and Clinical Course; 3.4.4 Initial Evaluation and Differential Diagnosis; 3.4.5 History of Pharmacological Treatment; 3.4.6 Current Approach to Treatment; Additional Reading; 4 SCHIZOPHRENIA; 4.1 Brief Description and Diagnostic Criteria; 4.2 Prevalence and Risk Factors
4.3 Presentation and Clinical Course4.4 Initial Evaluation and Differential Diagnosis; 4.5 History of Treatment; 4.6 Current Approach to Treatment; 4.6.1 Prodromal Phase; 4.6.2 Acute Phase; 4.6.3 Maintenance Phase; 4.6.4 Residual Phase; 4.7 Treatment Resistant Schizophrenia; Additional Reading; 5 ANXIETY DISORDERS; 5.1 Introduction; 5.1.1 History of Anxiety Disorders; 5.1.2 Anxiety Symptoms; 5.1.3 Brief Overview of the Anxiety Disorders; 5.1.4 History of Pharmacological Treatment for Anxiety; 5.2 Panic Disorder; 5.2.1 Brief Description and Diagnostic Criteria
5.2.2 Prevalence and Risk Factors5.2.3 Presentation and Clinical Course; 5.2.4 Initial Evaluation and Differential Diagnosis; 5.2.5 History of Pharmacological Treatment; 5.2.6 Current Approach to Treatment; 5.3 Generalized Anxiety Disorder; 5.3.1 Brief Description and Diagnostic Criteria; 5.3.2 Prevalence and Risk Factors; 5.3.3 Presentation and Clinical Course; 5.3.4 Initial Evaluation and Differential Diagnosis; 5.3.5 History of Pharmacological Treatment; 5.3.6 Current Approach of Treatment; 5.4 Obsessive-Compulsive Disorder; 5.4.1 Brief Description and Diagnostic Criteria
5.4.2 Prevalence and Risk Factors
Record Nr. UNINA-9910841538403321
Kelsey Jeffrey E  
Hoboken, N.J., : Wiley-Liss, c2006
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Psychological Measurements in Psychopharmacology / / editors, P. Pichot, R. Olivier-Martin
Psychological Measurements in Psychopharmacology / / editors, P. Pichot, R. Olivier-Martin
Autore Pichot P
Pubbl/distr/stampa Basel : , : S. Karger, , 1974
Descrizione fisica 1 online resource (VI + 267 pages) : : 25 figures, 54 tables
Disciplina 616.8/918/08 s
615/.78
Soggetto topico Psychiatry
Metabolism
Pharmaceutics
Pharmacology
Psychology
ISBN 3-318-03962-4
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910158720803321
Pichot P  
Basel : , : S. Karger, , 1974
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui